[Protective effects of modified recombinant human acidic fibroblast growth factor on small intestine after ischemia/reperfusion injury in rats].
OBJECTIVE
To explore the protective effect of modified recombinant human acidic fibroblast growth factor (rhaFGF) on small intestinal after ischemia/reperfusion (I/R) injury in rats.


METHODS
The clamp on the superior mesenteric artery (SMA) was removed after clamping it for 45 minutes to replicate I/R injury of the intestine in the rat. Rats were then divided randomly into sham operation group, normal saline treatment group and rhaFGF treatment group, in which the rats of the normal saline treatment group were injected 0.1 ml of normal saline and that of the rhaFGF group were given 4 microg of rhaFGF immediately after reperfusion. The content of D-lactate in the plasma was determined and the changes in intestinal pathology were observed. At the same time, the rates of apoptosis of intestinal epithelial cells were assessed 2, 6, 12 and 24 hours after I/R, and compared to the sham operation group.


RESULTS
The plasma content of D-lactate in the saline treatment group at 6 hours after I/R reached (0.34+/-0.09) mg/L and was significantly higher than that in the rhaFGF treatment group((0.23+/-0.07)mg/L, P<0.05). It was shown histologically that the intestinal structures were damaged more seriously in saline treatment group than in rhaFGF group. The apoptosis rates in the saline treatment group and rhaFGF group were elevated significantly, peaking at 12 hours after I/R injury((62.8+/-1.7)% in saline group and (42.5+/-2.6)% in rhaFGF treatment group), then the rate began to fall. There was statistically significant difference between the two groups at 12 hours after I/R injury.


CONCLUSIONS
rhaFGF can reduce content of D-lactate in the plasma and rate of apoptosis of epithelial cells in the intestine after I/R injury, thus it seems to afford a protective effect on the small intestine after I/R injury in rats.
Sun
Tong-zhu
TZ
Key Laboratory of Wound Repair, 304th Clinical Department of General Hospital of PLA, Beijing 100037 China.
Fu
Xiao-bing
XB
Chen
Wei
W
Zheng
Shu-yun
SY
Weng
Li-xin
LX
Zhao
Jing-yu
JY
Li
Jun-you
JY
Sun
Dan
D
D000818:Animals; D017209:Apoptosis; D004195:Disease Models, Animal; D004847:Epithelial Cells / Q000473:pathology; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology*; D006801:Humans; D007421:Intestine, Small / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D019344:Lactic Acid / Q000097:blood; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
D016220:Fibroblast Growth Factor 1; D019344:Lactic Acid